Results of the Phase III SAKK 35/03 Trial of Rituximab Maintenance for a Maximum of 5 Years in Follicular Lymphoma


Results of the Phase III SAKK 35/03 Trial of Rituximab Maintenance for a Maximum of 5 Years in Follicular Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Taverna CJ et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Results of the randomized Phase III trial SAKK 35/03. Proc ASH 2013;Abstract 508.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.